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Introduction: Sarcoidosis is a complex systemic disease with a silent, long-term evolution, and 
a heterogeneous clinical presentation. The diagnostic approach is complex with no single 
diagnostic test that may confirm the disease.  
Areas Covered: A large list of serum biomarkers has been tested during the last 40 years. In 
this review, we analyse the potential usefulness in the diagnosis and prognosis of sarcoidosis 
of serum biomarkers classified according to their corresponding cellular source. 
Expert commentary: Diagnosis of sarcoidosis must always be approached as a multistep 
process based on a case-by-case integration of clinical, radiological, histological and serological 
data, none of which being pathognomonic. We found sIL-2R, CRP, SAA and chitotriosidase to 
be the best markers to confirm sarcoidosis (highest sensitivity), while ACE, gammaglobulins 
and lysozyme may be more useful for discarding sarcoidosis (highest specificity), taking into 
account that with the use of a higher cut-off we can increase specificity and with a lower cut-
off we can increase sensitivity. Other biomarkers (TNF-a and CCL18) could help to identify 
patients with an enhanced risk of developing pulmonary fibrosis or progressive disease. The 
future scenario of the serological diagnostic approach of sarcoidosis will be the use of multi-
assays including biomarkers from different cellular sources. 
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Sarcoidosis is a systemic disease characterized by the development of non-caseating epitheloid 
granulomas affecting overwhelmingly thoracic organs (the lungs and lymph nodes) in more 
than 90% of patients), although extrathoracic involvement has been reported in nearly half the 
cases (1). The diagnostic approach is complex with no single diagnostic test that may confirm 
the disease, and with no standardized classification criteria internationally accepted. In clinical 
practice, a patient is diagnosed with sarcoidosis on the basis of a compatible clinical and/or 
radiological picture together with histopathologically-proven non-caseating granulomas, 
always excluding other diseases with similar clinical or histolopathological features (2). Since 
most patients with sarcoidosis have thoracic involvement, chest radiograph has played a key 
diagnostic role for decades, now replaced by high-resolution computed tomography (CT) and 
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in complex cases. Certain 
highly-specific clinical presentations of sarcoidosis (Löfgren and Heerfordt syndromes) or 
patients presenting with thoracic stage I (bilateral hilar lymphadenopathy unrelated to 
infectious or neoplasic diseases) are often diagnosed clinically with sarcoidosis avoiding the 
need for histopathological confirmation (3). In complex cases, however, pathologic 
confirmation of noncaseating granulomas is necessary and biopsy should be obtained from the 
most accessible and safest anatomical site (3). 
Since laboratory work-up alone cannot diagnose the disease, serum biomarkers have been 
always considered of little usefulness in the diagnosis and prognosis of sarcoidosis. A large list 
of biomarkers has been tested during the last 40 years, although only one (angiotensin-
converting enzyme, ACE) is often used in clinical practice. However, the clinical usefulness of 
ACE measurement  is often associated with significant limitations (low specificity test, large 
interindividual variability in the results, inconsistent correlation between serum levels and 
disease expression) (4–6). 
The non-caseating granuloma is the pathological hallmark of sarcoidosis, formed through the 
recruitment of different cell types, mainly monocyte-macrophages, T and B cells and 
epithelioid cells as a consequence of an abnormal autoimmune response involving both 
adaptive and innate immune systems (7). In this review, we analyse the potential usefulness of 
serum biomarkers classified according to their corresponding cellular source in the diagnosis 
and prognosis of sarcoidosis. 
 
2. Monocyte/macrophage-related markers 
Macrophages and CD4+ T cells are the key cellular players in the granulomatous reaction and 











architectural basis of sarcoid granulomas and the enhanced local expression of macrophage-
derived molecules induces and maintain an inflammatory response further amplified by the 
recruitment of other immune cells into the targeted tissues (7). 
 
2.1. Angiotensin-converting enzyme (ACE) 
Angiotensin convertase enzyme (ACE) is an acid glycoprotein with a molecular weight of 
140,000 d that converts a decapeptide (angiotensin I) to an octapeptide (angiotensin II) by 
cleaving the dipeptide histidine and leucine C-terminal, resulting in a vasoactive molecule that 
plays a key role in regulating blood pressure and electrolyte balance. ACE may be secreted by 
monocytes, macrophages and epitheloid cells (4–6) and is involved in the pathogenesis of 
sarcoidosis as an important modulator of granuloma formation (6).  
Serum ACE activity has been used as a diagnostic marker of sarcoidosis since 1975 when 
Lieberman (8) reported raised serum ACE levels in 15 of 17 patients with active sarcoidosis; in 
1981, the Ninth International Conference of Sarcoidosis recommended the measurement of 
serum concentrations of ACE as a useful diagnostic and prognostic tool. In addition to the 
classical spectrophotometric assay used by Lieberman, other methods have been reported, 
including spectrofluorimetric, colorimetric and radio assays, with variable cut-offs that may 
include either lower (20-30 IU/mL) or higher (70-80 U/L) values, although most of the studies 
published in the last 10 years are using techniques with cut-offs between 50 and 70 IU/L (Table 
1). Serum ACE activity is not influenced by human gender, although children and young adults 
may have higher ACE levels than older people. However, ACE concentrations are genetically 
influenced, since an insertion (I)/deletion (D) polymorphism in the ACE gene has been 
associated with significant variations in serum levels (9), with homozygous carriers of the 
deletion (DD) or insertion (II) express the highest and lowest ACE levels, respectively, whereas 
heterozygous ID individuals express intermediate ACE levels (10), with significant variations 
between Caucasians and Asians; unfortunately, the use of a genotype-specific reference range 
slightly increased the diagnostic sensitivity of the standard serum ACE measurement at the 
expense of lowering the specificity of the test (11). In addition, serum ACE levels are uniformly 
low if the patient is receiving ACE-inhibitor medications (6). 
Raised serum ACE levels have been reported in 1385 (55%) out of 2529 patients with 
sarcoidosis included in 16 studies published in the last 20 years (Table 1) (12–27) , with a wide 
range of frequencies including 40% as the lowest (16) and 86% as the highest (18). Raised 
serum concentrations of ACE have been reported in other diseases related to an enhanced 
monocyte-macrophage activation, including granulomatous infections (tuberculosis, leprosy), 











endocrine diseases (diabetes mellitus, hyperthyroidism) and liver cirrhosis, while serum ACE 
levels are reduced in patients with Crohn's disease (4,6). In Table 2 (15,18,20,25,28–32), we 
summarize the sensitivity and specificity values of the main studies reported in the last 20 
years. Two studies in patients with uveitis with a similar cut-off (51-52 U/L) reported a 
sensitivity of 54-77% and specificity of 70-88% for the use of serum ACE levels to confirm 
sarcoidosis in patients presenting with uveitis (25,28); Niederer et al (25) reported that ACE 
had a very high negative predictive value for sarcoid uveitis (normal levels of serum ACE may 
obviate further investigations for sarcoidosis in most patients), and that the highest positive 
predictive value was reported in patients presenting with intermediate uveitis or panuveitis. In 
unselected sarcoidosis, the two studies with a similar cut-off (17-21 U/L) showed a sensitivity 
of 68-71% and specificity of 71-75% to distinguish between sarcoidosis and healthy controls 
(30,31). 
Several studies have evaluated the clinical usefulness of measuring serum ACE levels in 
patients with sarcoidosis (Table 3). With respect to pulmonary involvement, there are more 
studies reporting a lack of correlation between serum ACE levels and radiological thoracic 
stages or pulmonary involvement than studies reporting a positive correlation. Some studies 
have reported increased ACE levels in patients with radiological stage I or in those with 
bilateral hilar lymphadenopathies -BHL- (14,33), while others reported normal or even reduced 
levels in patients with erythema nodosum (34) or Lofgren syndrome (35). From a therapeutic 
view, most studies have reported a reduction of serum ACE levels after treatment with 
corticosteroids (18,36–40), chloroquine (41) or infliximab (42,43). Although elevated serum 
ACE levels at diagnosis are not an indication to start systemic treatment (6), it can be helpful in 
monitoring the therapeutic response after initiation of treatment (25,26). In contrast, the 
usefulness of serial measurement of serum ACE levels to assess the prognosis and outcome of 
sarcoidosis is unclear: some studies have reported higher ACE levels in patients with active 
disease (32,33,44,45) and in those with progressive/chronic disease (22,35,39), although a 
similar number of studies have reported negative correlations (32,46–51). 
 
2.2. Chitotriosidase 
Chitotriosidase is a member of a family of glycosylhydrolases enzymes (also called chitinases) 
involved in the degradation of chitin, a N-acetylglucosamine polymer secreted by fungi or 
parasites (4). Chitin-producing microorganisms activate macrophages and neutrophils that 
secreted the enzyme (52). 
Chitotriosidase is a specific marker of macrophage activation and the principal biochemical 











with atherosclerosis, b-thalassemia, malaria and visceral leishmaniasis (54–57). Chitotriosidase 
activity can be determined in serum by a fluorimetric test (58), with cut-offs ranging between 
48.8 and 100 nmol/h/mL (32,59,60). Significantly raised levels have been reported in patients 
with sarcoidosis in comparison with patients with tuberculosis, asbestosis, idiopathic 
pulmonary fibrosis or systemic sclerosis (61,62). The sensitivity and specifity rates were 48.8% 
and 88.8% for the lowest cut-off (48.8) (59), respectively, while for a higher cut-off (100) the 
figures were 82.5% and 70% (32).  
With respect to clinical correlations with phenotype and outcome, several studies have 
reported higher serum levels of chitotriosidase in patients with pulmonary involvement 
demonstrated by abnormal imaging or functional studies (32,59,63). Two studies reported a 
reduction of chitotriosidase serum levels after treatment with corticosteroids or after adding 
an imunosuppresive agent (59,60). In a follow-up study, there was a positive correlation with 
clinical, radiological and functional worsening, with levels increasing significantly in patients 
who relapsed during the follow-up (63). Several studies have found a good correlation with 
active disease (32,60), clinical outcome status (32) and disease progression (59). 
 
2.3. Lysozyme 
Lysozyme (or muramidase) is a bacteriolytic enzyme, produced by monocytes and 
macrophages, discovered in 1922 by Fleming who reported that it had antibacterial activity 
through cleavage of b1-4 glycoside bonds in bacterial cell walls. Lysozyme is located into the 
granules of monocytes, macrophages, and polymorphonuclear leukocytes, whence it may be 
released into biologic fluids. In sarcoidosis, lysozyme is mainly produced by macrophages and 
epithelioid cells forming the granuloma. Serum levels of lysozyme are not influenced by gender 
or smoking (64), while renal dysfunction may increase circulating levels because lysozyme is 
filtered by renal glomeruli. Elevated serum levels have been reported in pulmonary 
tuberculosis and pneumoconiosis (silicosis, asbestosis, and berylliosis) (18,37,39). In patients 
with uveitis, two studies have reported significantly raised serum levels of lysozyme in patients 
with sarcoid uveitis in comparison with those with other underlying diseases (ankylosing 
spondylitis, Behçet disease, tuberculosis or syphilis) (15,65). 
Serum lysozyme levels are elevated in 162 (66.4%) out of 244 patients with sarcoidosis 
included in 7 studies published in the last 10 years (14,15,17,27,60,66,67), with a very wide 
range of frequencies including 29% as the lowest (67) and 84% as the highest figure (27). The 
cut-offs vary according to the technique used, although most of the studies published in the 











Some studies have reported a good correlation between raised serum levels of lysozyme and 
parenchymal pulmonary infiltration (14,48,68). The association between serum lysozyme 
levels and extrapulmonary sarcoidosis is unclear, one study reported a good correlation with 
extrathoracic involvement (68) while Nguyen et al described no significant association either 
with multiple organ involvement or with BHL (14). Two studies reported a reduction of 
lysozyme levels after treatment with corticosteroids (37,39) (Table 3). 
 
2.4. Neopterin 
Neopterin or trihydroxypropylpteridin is a precursor of biopterin, a metabolite of guanosine 
triphosphate, an essential cofactor in neurotransmitter synthesis. It is released in vitro from 
monocytes/macrophages stimulated by interferon-gamma (4,6). Serum neopterin levels are 
highly sensitive (95%) but rather less specific (45%) (69), although a recent study have 
reported inverse figures (80% and 100%, respectively) (70).  
The values are higher in patients with advanced chest radiographic stages II-III (51), in those 
with an acute clinical onset and in those requiring long-term therapy (51), and also correlated 
with an active disease disclosed by PET (70). 
 
2.5. Cytokines and chemokines 
Monocyte-macrophage lineage cells are the origin of an enhanced local expression of a large 
number of cytokines and chemokines, responsible for the attraction of T-cells at the targeted 
tissues, including cytokines overwhelmingly involved in promoting Th1/Th17 differentiation 
(IL-2, IL-8, IL-12, IL-15, IL-18, and Th17-related IL-17 and IL-22) (71), and a large variety of 
chemokines, such as CCL5 (RANTES), CCL9 (MIG), CCL10 (IP-10) and CCL18 (or PARC) (4,7). 
Among the molecules evaluated at least in 2 different studies in the last 20 years, the more 
solid and potentially useful results are reported for CXCL10 levels, that were significantly 
higher in 5 different studies in comparison with both healthy controls and patients with uveitis 
caused by other etiologies (47,72–75), as well as for CXCL9 (47,74) and CC16 (76,77). Among 
cytokines, highly significant levels are reported for IL-18 (78–80), IL-12 (81,82) and TNFa 
(75,83) in comparison with healthy controls (Table 4). 
 
3. T-cell activation markers 
The inflammatory mediators produced by the macrophages involved in the granuloma 
formation trigger the recruitment of additional immune cells, especially CD4+ Th cells, that 











early phases, the microenvironment at the sites of active disease is characterized by a highly 
polarized Th1/Th17 profile (7). 
 
3.1. Soluble Interlukin-2 receptor 
Activation of CD4+ lymphocytes leads to the expression of IL-2 receptors on the cell surface 
with shedding of soluble IL-2 receptor (sIL-2R) into the circulation; therefore, serum sIL-2R is 
considered a reliable serological marker of T-cell activation (5). Serum IL-2R levels can be 
elevated in several infections (HIV, tuberculosis, leprosy), lymphoproliferative disorders 
(lymphoma and leukemia) and other inflammatory conditions (idiopathic pulmonary fibrosis, 
scleroderma, rheumatoid arthritis, systemic lupus erythematosus , Graves' ophthalmopathy, 
and cardiac and renal allograft rejection) (5,6). Semenzato et al (84) reported in 1987 raised 
serum levels of IL-2R in patients with sarcoidosis, and further studies have reported raised 
levels are elevated in 176 (57%) out of 308 patients with sarcoidosis (14,24,29,43,49,85), with 
a very wide range of frequencies including 30% as the lowest (14) and 100% as the highest 
figure (85). With respect to diagnostic accuracy, the figures ranged from 63 to 82% for 
sensitivity, and from 57 to 100% for specificity in studies differentiating between healthy 
controls and unselected cases of sarcoidosis (30,31,70,86,87), while for patients with ocular 
sarcoidosis, the figures were 92-98% for sensitivity and 26-94% for specificity (28,29). In the 
study by Rothkrantz-Kos et al (31), an increase of the cut-off increased both sensitivity and 
specificity, respectively, while a decrease of the cut-off increased sensitivity but decreased 
specificity; in the study by Groen-Kahan et al (28) in patients with ocular sarcoidosis, specificity 
increased from 26% to 64% after increasing cut-off until >4000 pg/mL.  
Several studies showed that serum IL-2R levels correlated with radiographic stage of disease 
(Table 3), but the results were heterogeneous: some studies found higher levels in patients 
with pulmonary parenchymal involvement (14,48) while other studies reported high levels 
mainly in patients with no pulmonary involvement including those with stage I (87),  BHL (14) 
or erythema nodosum (87). In contrast, the association with extrapulmonary activity was 
confirmed by several studies (14,50,87–89). Some studies have reported a good correlation 
between changes in sIL-2R level and treatment response showing a reduction in serum sIL-2R 
levels after corticosteroid therapy (90,91) or after treatment with infliximab (42,43), while no 
therapeutic correlation was informed in another cohort (87). High serum sIL-2R levels have 
been associated with acute or active disease (51,90), with disease progression over the next 6 
months in untreated patients (92), or in patients requiring long-term therapy (51); however, a 












3.2. Other cytokines 
T helper (Th) cells are characterized by different patterns of cytokine secretion which are used 
to define their subsets: Th1 cells are characterized by secreting interferon-gamma (IFN-γ) and 
tumor necrosis factor alpha (TNF), Th2 cells by secreting IL-4, IL-5 and IL-13, Th9 cells by 
secreting IL-9 and Th17/22 cells by secreting IL-17 and IL-22 (94). The local cytokine milieu that 
drives histopathological abnormalities sarcoidosis represents a pivotal immunological 
characteristic for this disease. Sarcoidosis remains defined as a disease characterized by 
enhanced expression of interferon-gamma (47), but more recently there has been evidence to 
suggest that the origin of this may be from lymphocytes of Th1 and / or Th17 lineage (95); 
recently, a subset of lymphocytes bearing a Th17 phenotype were identified to be a significant 
contributor to IFNg-expressing cells in sarcoidosis (96). Other studies have tested serum Th 
cytokine levels (Table 3): two studies have reported raised levels of TNF alpha in patients with 
sarcoidosis in comparison with healthy controls (75,83), with no significant results about the 
mean serum levels of interferons (alpha and gamma), IL4 and IL-6 (75).  
 
4. B-cell-related markers 
Despite the central involvement of cellular immunity in the pathogenesis of sarcoidosis, 
several studies have suggested an etiopathogenic role of B cells. In the early non-
granulomatous lesions (lymphocytic infiltrates), Th infiltration is often accompanied by the 
presence of plasma cells and immunoglobulin deposits, suggesting a local hyperactivity of the 
B-cell immune system (97). In fact, patients with active sarcoidosis have an abnormal 
peripheral B-cell profile including significantly less circulating CD27+ memory B cells and 
increased circulating transitional B cells and Bregs producing IL-10 in comparison with healthy 
donors or patients with inactive sarcoidosis (98,99). A recent open-label study has treated 10 
patients with 2 doses of 1 g of rituximab 2 weeks apart with improvement in FVC and/or 6-min 
walk in 7 patients at week 24 (100). 
 
4.1. Lymphocyte count 
Three studies have reported a lower white cell count in 81/321 (25%) patients, while 
lymphopenia has been reported in 40/246 (16%) patients (101–103). Several studies have 
specifically evaluated the clinical significance of lymphopenia that was associated with a worse 
prognosis of the disease (101,102), including severe internal organ involvement (104), 
extrathoracic disease (105), higher disease activity (106) or requirement of GC for severe 
disease (101). In addition, a significant higher frequency of lymphopenia is reported in patients 











a therapeutic point of view, Crouser et al (108) have proposed that the presence of 
CD4(+) lymphopenia may identifiy a specific phenotype particularly responsive to anti-TNF 
agents, after reporting 5 patients with CD4(+) lymphopenia who improved clinically after being 
treated with infliximab and that showed a significant increase in absolute peripheral blood 
lymphocyte and CD4(+) T-cell counts.  
 
4.2. Gammaglobulins 
Belhomme et al (109) have reported hypergammaglobulinemia (>13.5g/L) in nearly 40% of 
patients with sarcoidosis, with a median immunoglobulin level significantly higher in some 
epidemiological and clinical subsets (BAA patients, extrapulmonary involvement, requiring a 
treatment or relapsing patients), while lower levels were reported in patients presenting with 
a Löfgren’s syndrome; in this study, immunoglobulin levels improved the capacity of a 
statistical model to predict relapse. In patients with uveitis, the frequency of 
hypergammaglobulinemia was nearly 5-fold higher in those with sarcoidosis in comparison 
with patients presenting uveitis of other etiologies (27% vs 6%) (102). 
 
4.3. b2-Microglobulin 
Beta2-Microglobulin is a low-molecular-weight protein produced by all cells (except mature 
red cells) that is considered a good serum biomarker of lymphocytic activation. In 1982, Parrish 
et al (110) reported raised levels of beta 2-microglobulin in 63% of patients with sarcoidosis, 
with no correlation with thoracic stages, duration of disease or requirement of corticosteroid 
treatment, and further studies confirmed higher levels in comparison with healthy controls. In 
1987, Selroos et al (111) measured beta2-microglobulin in the serum of 107 patients with 
sarcoidosis and found increased levels in patients with acute sarcoidosis, normal or slightly 
raised levels in those with newly-detected sarcoidosis but without erythema nodosum, and 
normal levels in patients with chronic active sarcoidosis or in those with resolved sarcoidosis.  
 
4.4. BAFF 
B cell activating factor (BAFF) is a cytokine that play a major role in the maintenance of B cell 
homeostasis. Three recent studies have evaluated the clinical usefulness of measuring serum 
BAFF levels in patients with sarcoidosis, and found higher levels in patients with active 
sarcoidosis with a strong correlation with serum hypergammaglobulinemia (98) and with the 
disease severity score (112), and a higher frequency of skin and eye involvement in patients 












5. Acute phase reactant proteins 
The systemic release of pro-inflammatory cytokines (TNF, IL-1, IL-6) by activated immune-
related cells (leucocytes, macrophages, monocytes, fibroblasts and endothelial cells) may 
trigger the so-called hepatic acute-phase response. C- reactive protein and amyloid A are the 
main acute-phase proteins released by the liver, and several studies have reported high levels 
of these reactants in patients with sarcoidosis. 
 
5.1. CRP 
Serum CRP levels are elevated in 202 (48.9%) out of 413 patients with sarcoidosis included in 3 
studies (16,107,114), with a quite homogeneous range of frequencies (47-58%), with the cut-
off often used being of 10 mg/L. Raised levels have been associated with fatigue (115), Lofgren 
syndrome (35,114) and lower functional lung tests (114), with no correlation  between serum 
CRP levels and clinical course (47). CRP levels were useful to confirm sarcoidosis in patients 
presenting with myelitis (107) and may predict the effectiveness of infliximab in chronic 
pulmonary sarcoidosis (116). Two studies have also analysed the usefulness of high-sensitivity 
CRP levels (31,117), reporting higher significant levels with respect to healthy controls, with a 
high specificity (91%) and lower sensitivity (53%). 
 
5.2. Serum amyloid A 
Serum amyloid A (SAA) is an acute-phase reactant related to high-density lipoprotein 
cholesterol. In sarcoidosis, SAA regulates granulomatous inflammation through Toll-like 
receptor-2 (118). Several studies have reported significantly higher serum SAA levels in 
patients with sarcoidosis in comparison with healthy control populations, with a very-high 
sensitivity rate (96%) and low specificity rates (37-52%) (31,119).  
The results with respect to a potential clinical significance og high serum SAA levels are 
inconsistent, with no correlation with pulmonary involvement (48,120). Some studies reported 
a correlation with disease activity (50,121), and others showed no correlation with 
extrapulmonary involvement (50) or with disease progression (48). 
 
5.3. ESR 
Two studies have evaluated the usefulness of ESR levels, with higher values in around 40% of 
patients (17), and higher mean values with respect to healthy controls, but with no correlation 
with the clinical course of the disease (47). 
 











6.1. Bronchial epithelium activation markers 
Bronchial epithelium may contribute to the initiation and perpetuation of inflammatory 
processes. Bronchial epithelial cells are able to release a large number of mediators, not only 
cytokines and chemokines, but also growth factors and other molecules involved in innate 
immunity processes, which are able to regulate the recruitment, activation, and differentiation 
of immune cells. Serum levels of several epithelium-related molecules have been tested as 
potential biomarkers in patients with sarcoidosis. 
Krebs von den Lungen 6 (KL-6) is a mucinous glycoprotein expressed on the surface membrane 
of alveolar and bronchiolar epithelial cells. Raised serum KL-6 levels are reported in a variety of 
pulmonary diseases such as radiation pneumonitis, drug induced pneumonitis, and interstitial 
lung disease  (122–124). In patients with sarcoidosis, higher serum levels of KL-6 have been 
reported in comparison with healthy controls (77)  
Several studies have demonstrated a close correlation between high KL-6 serum levels and 
pulmonary involvement, including a positive correlation with CT abnormalities (ground-glass, 
nodules, septal thickening and traction bronchiectasis) (125), radiological stages II/III (77,122), 
parenchymal infiltration (48), pulmonary gallium-67 scan uptake, BAL lymphocytosis (122), and 
progressive disease (48,77) (Table 3). In Japanese patients with uveitis, raised KL-6 levels may 
help in identifying sarcoidosis from other etiologies of uveitis (126,127), although no 
correlation with therapeutic response to corticosteroids was reported. KL-6 has demonstrated 
a weak predictive power to identify disease persistence or progression (48,77).  
Raised serum levels of surfactant protein D (SP-D) have been reported in non-smoking patients 
with sarcoidosis in comparison with healthy controls (77), and in patients with uveitis related 
to sarcoidosis with respect to patients with uveitis of other etiologies (128). Other studies have 
reported significantly higher serum levels of a large number of markers in comparison with 
healthy controls, including ICAM-1 (129), VCAM-1 (130), EGF (75), VEGF and PDGF (131), alpha-
defensin (132), cathelicidin (133), ficolin-3 (134), NGAL (135), CD163 (136), tryptase (137) and 
YKL-40 (138). 
 
6.2. Cardiovascular markers 
With respect to cardiac biomarkers, Date et al (139) reported a median plasma BNP levels 
significantly higher in patients with cardiac sarcoidosis than in those with pulmonary 
sarcoidosis, while Kiko et al (89) also reported BNP as a useful marker for detecting cardiac 
involvement in sarcoidosis and high-sensitivity cardiac troponin T (troponin I) as a predictor of 
fatal arrhythmia. Kandolin et al (140) measured troponin I in 62 patients with new-onset 











ventricular ejection fraction was significantly reduced in those with raised troponin I levels, 
and that raised levels normalized after 4 weeks of glucocorticosteroid therapy; in addition, 
only 67% of patients with raised levels were free of cardiac events in a two-year follow-up in 
comparison with 93% of those with baseline normal levels. Baba et al (66) have reported that 
measurement of troponin I have a sensitivity and specificity of 87.5% and 75.0%, respectively, 
to detect active cardiac involvement confirmed by 18F-FDG PET findings. Finally, two studies 
have reported raised serum D-dimer levels in 20 (34.5%) out of 58 patients with sarcoidosis 
(141,142). 
 
7. EXPERT COMMENTARY 
7.1. Reliability and validity of diagnostic tests in sarcoidosis 
There has been a long controversy about the limited reliability and validity of serum 
biomarkers as diagnostic tests for sarcoidosis (5). Reliability and validity are measures of 
diagnostic test performance, but they have separate and distinct meanings. Reliability (i.e., 
reproducibility or precision) refers to the capacity of a diagnostic test to give the same result 
on repeated measurements, and depends on the method of measurement and the variability 
in the specific disease on which the test is applied (143). In sarcoidosis, reliability of the most 
frequently tested serum biomarkers is poor, with a wide heterogeneity of techniques and cut-
offs reported for these markers. The lack of a standardized international recommendations 
does not allow a homogeneous interpretation of those studies testing for a specific biomarker. 
In contrast to reliability, validity (i.e., accuracy) is the degree to which the data measure what 
they are intend to measure when compared with a confirmatory diagnostic test (often known 
as ‘‘gold standard’’) classifying subjects into a dichotomous category (diseased versus non-
diseased) (143). In a diagnostic process, validity is described in terms of sensitivity (i.e., the 
rate of subjects with the disease who have a positive test) and specificity (i.e., the rate of those 
without the disease who have a negative test) (143). In sarcoidosis, the lack of an adequate 
“gold-standard” test complicates the analysis of any diagnostic test in terms of sensitivity and 
specificity. In addition, most studies measure sensitivity and specificity of a specific serum 
biomarker in sarcoidosis with respect to the values observed in healthy controls, an approach 
that although is methodologically correct, is not useful in daily practice in which biomarkers 
are mainly required for distinguishing between sarcoidosis and other similar diseases. Very few 
studies have included a control population with other similar diseases to sarcoidosis, not only 
pulmonary but also systemic diseases. 
In the last 40 years, the usefulness of serum biomarkers in diagnosing sarcoidosis has been 











never applied in other complex systemic autoimmune diseases. Biomarkers should be 
considered a support for a suspected diagnosis of sarcoidosis, taking always into account the 
clinical context where we are searching for the diagnosis. Although the ideal diagnostic test 
should be both highly sensitive and highly specific, this is not usual in single markers testing 
complex diseases, as increasing sensitivity rate decreases specificity, and viceversa; this is the 
reason why these heterogeneous diseases are always diagnosed using a combination of 
various features (classification criteria); in addition, different clinical scenarios may require 
tests with different sensitivity and specificity rates (143). In the diagnostic workup of a patient 
with a suspected sarcoidosis, high sensitivity tests will be especially useful due to their highest 
ability to correctly classify the suspected individual as ′diseased′, together with tests with high 
positive predictive values (PPV, percentage of patients with a positive test who actually have 
the disease) (144). In contrast, tests with high specificity and NPV will be useful mainly to 
discard sarcoidosis in some complex severe involvements in which a biopsy cannot be 
performed (i.e., cardiac and neurosarcoidosis) (Figures 1 & 2). 
 
7.2. Multiple measurement of biomarkers 
When raised levels of a specific biomarker for sarcoidosis (usually raised ACE levels) are 
accompanied by several other clues that physicians look for in diagnosing the disease, it may 
be a strong indication to consider sarcoidosis as a reasonable diagnostic option. But probably it 
could be more useful to test for a panel combining multiple markers than not testing a unique 
marker. There is a large variety of available markers from different cellular origin and with a 
differentiated balance between specificity and sensibility, and a simultaneous multiple 
measurement probably will cover better the diverse clinicopathological scenarios that may 
arise at diagnosis of sarcoidosis. Few studies have combined more than one serum biomarker. 
In 1987, Selroos and Klockars (111) measured serum concentrations of ACE and b2-
microglobulin in patients with sarcoidosis in different clinical stages and found that b2-
Microglobulin levels correlated better with early disease stages (granuloma formation) and 
ACE values with later etiopathogenic phases (granulomatous disease). In 2011, Mostard et al 
(70) measured ACE, sIL-2R and neopterin and found that sensitivity of combined serological 
biomarkers for the presence of inflammatory activity as detected by PET was 80% and 
specificity 100%. In a recent study in patients with uveitis, Groen-Hakan et al (28) tested 249 
patients for detecting underlying sarcoidosis using ACE and sIL-2R serum levels, and found that 
the combined measurement of the two markers was not superior to the use of each marker 
individually in terms of validity; interestingly, sensitivity of chest X-Ray (56%) was quite similar 











Beirne et al (145) measured 30 circulating biomarkers in 20 patients with systemic sclerosis 
and 21 with sarcoidosis, and found raised levels of IL-1, -6, -8, TNF-RI, TNF-RII and growth 
factors EGF and HGF in both diseases, although only Th1 chemokines (IP-10, MIG, MIP-1α, 
MIP-1β and RANTES) were specifically raised in sarcoidosis. Loza et al (146) carried out a 92-
analyte multiplex panel to assess the expression of serum proteins in 134 sarcoidosis patients 
compared with sera from 50 healthy controls, and found 29 markers significantly elevated in 
sarcoidosis, including chemokines, neutrophil-associated proteins, acute-phase proteins, and 
metabolism-associated proteins (CD40L, brain-derived neurotrophic factor (BDNF), epidermal 
growth factor (EGF), CC-chemokine ligand 5/RANTES, myeloperoxidase, TNF-α levels, MIP-1β 
and ENA-78 (epithelial-derived neutrophil-activating protein 78). Those patients expressing the 
highest levels of TNF-α were those who had more severe disease and that following infliximab 
treatment, had the greatest improvement in pulmonary functional tests together with a 
reduction in serum levels of the inflammatory proteins MIP-1β and TNF-RII.  
 
7.3. Clinical staging and therapeutic response 
There is no current information about which or how many biomarkers are needed to 
characterize a specific clinical pattern, but some studies have evaluated certain molecules as 
early markers of progression toward chronic refractory disease, as predictors of disease 
relapse, or as markers of therapeutic response. The most solid association linked raised serum 
CTO and KL-6 levels with pulmonary involvement. With respect to the usefulness of serum 
biomarkers for predicting disease progression, the results were inconclusive for ACE and sIL-
2R, since the number of studies reporting a significant correlation was similar to those that 
reported non-significant associations (Table 4); in contrast, most studies testing CTO (59,63) 
showed a good correlation with disease outcomes, including the prediction of relapses (63). 
With respect to therapeutic response, most studies showed the usefulness of measuring 
serum levels of ACE, chitotriosidase, sIL-2R and lysozyme (Table 4). 
 
7.4. Phenotyping systemic disease 
Another key message for daily practice is that the diagnostic validity of a specific biomarker 
may vary according to the clinical phenotype of sarcoidosis. Some studies have reported 
different validity rates of the same test in patients with a specific organ involved (ocular 
sarcoidosis) with respect to the values obtained in unselected populations of patients with 
sarcoidosis. In addition, some biomarkers seems to have a better ability in detecting 
sarcoidosis involving isolated organs (as has been reported for sIL-2R in pulmonary and cardiac 











(three or more different organs involved) as has been reported for ACE, lysozyme and IL-12 
(14,81). Even in patients with the same organ involved, different validity rates have been 
reported for the same biomarker among the different organ-specific types of involvement: in 
patients with uveitis, Niederer et al (25) have reported the highest sensitivity rate for ACE 
(82%) in patients presenting with intermediate/panuvetis, while the highest specificity rate 
(93%) was reported for those with posterior uveitis. Unfortunately, the association between 
raised levels of serum biomarkers and extrapulmonary or systemic sarcoidosis is unclear for 
the main markers (ACE, CTO, lysozyme and SAA), and only raised serum sIL-2R levels have 
been related to extrapulmonary involvement, not only for multiorgan disease but also for 
organ-specific involvements (skin, lymph nodes or spleen) (Table 4). 
 
8. 5-YEAR VIEW 
Sarcoidosis is a complex systemic disease with a silent, long-term pathological evolution, and a 
wide, heterogeneous clinical presentation. A large list of studies has tried to delineate clinical 
phenotypic subgroups that could predict the outcome of an individual patient and, therefore, 
to help the physician to decide specific diagnostic and therapeutic approaches. Considering the 
complexity and heterogeneity of sarcoidosis, “omics” and systems biology (147) may be future 
useful approaches to elucidate the biological mechanisms underlying the different disease 
phenotypes, and therefore, to identify more effective disease biomarkers (148). A recent 
review has analysed the application of these approaches to sarcoidosis research, including not 
only genome-wide association studies (GWASs), but also transcriptomic, proteomic, 
metabolomic and microbiomic studies (148). Several genetic studies have evaluated numerous 
gene expression signatures, while other studies have measured the whole blood transcriptome 
and the transcriptome of tissues. These studies have confirmed the predominant Th1 response 
in sarcoidosis and particularly the key role of interferon-γ (IFN-γ) and type I IFN-driven 
signaling pathways (149), including significant differences in enrichment of the interferon 
pathway (150), but have also identified new molecular mechanisms involving Tregs (reduced 
suppression activity), increased apoptosis or TLR-2 signaling inhibition pathways (151). The 
role of histopathological staining is also under investigation, and a recent study have reported 
that SAA staining of sarcoidosis granulomas has an overall specificity of 84% but with a low 
sensitivity (44%) (152). 
Metabolic changes may also play a role in perpetuation of granulomatous inflammation in 
sarcoidosis. Geamanu et al (153) have used 1H nuclear magnetic resonance (NMR)-based 
untargeted metabolomic analysis, and after the application of integrative pathway analyses, 











transmethylation metabolites, molecules that could be tested in further studies as potential 
biomarkers. With respect to microbiomic studies, a cross-sectional study compared the lung 
microbiota of 71 patients with sarcoidosis, and found that Atopobium spp and 
Fusobacterium spp were significantly more frequent in samples of patients with sarcoidosis in 
comparison with samples from healthy controls, with mycobacteria being found in only two of 
sarcoidosis samples (154). In contrast, a recent study using metagenomic sequencing have 
reported enrichment of microbes in sarcoidosis samples but with a limited concordance across 
sample types (155). 
 
9. CONCLUSIONS 
Diagnosis of sarcoidosis must be always approached as a multistep process based on a case-
by-case integration of clinical, radiological, histological and serological data, none of which 
being pathognomonic in and of itself. Many different mediators, such as cytokines, 
chemokines, and other proteins with various functions, are involved in its complex 
pathogenesis and some have been proposed as potential biomarkers. This review has been 
centered on serological biomarkers, although there is a large number of studies that have 
evaluated other fluids (overwhelmingly the BAL fluid, because lungs are the most frequently 
involved organ). However, the analysis of biomarkers in serum would be preferable, because 
they are less invasive than BAL to obtain, and because nearly one third of patients with 
sarcoidosis do not have pulmonary involvement. Unfortunately, and in spite of the large 
number of studies published, the low level of evidence (most studies are retrospective and 
cross-sectional studies) together with a wide methodological heterogeneity (serum cut-off 
levels, control populations, inclusion criteria, definition of the main outcomes, etc.) resulted in 
inconsistent findings that do not allow to offering solid clinical recommendations, although 
previous reviews have reported some subjective qualitative scores (5,6)). As a summary, we 
found sIL-2R, CRP, SAA and chitotriosidase as the best markers to confirm sarcoidosis (highest 
sensitivity), while ACE, gammaglobulins and lysozyme may be more useful for discarding 
sarcoidosis in complex cases (highest specificity), taking into account that with the use of a 
higher cut-off we can increase the specificity and with a lower cut-off we can increase the 
sensitivity of a diagnostic test. About prognosis, sIL-2R and chitotriosidase are probably better 
prognostic markers in comparison with ACE [10,35], although head-to-head comparisons are 
limited (Table 5) (32,35,48,50,51,59). Other mediators, such as TNF-a and CCL18, could help to 
identify patients with an enhanced risk of developing pulmonary fibrosis or progressive disease 
[64,96]. However, proper validation in large cohorts of patients is required for most 











be the use of multi-assays including biomarkers from different cellular sources, with a case-by-
case interpretation of the different sensitivity and specificity values of each test according to 















• Reliability of the most frequently tested serum biomarkers is poor (wide heterogeneity 
of techniques, cut-offs, outcome definition).  
• The diagnostic validity of a specific biomarker may vary according to the clinical 
phenotype.  
• sIL-2R, CRP, SAA and chitotriosidase may be good markers to confirm sarcoidosis (high 
sensitivity) 
• ACE, gammaglobulins and lysozyme may be more useful for discarding sarcoidosis in 
complex cases (high specificity) 
• Biomarkers should be viewed as a support for a suspected diagnosis of sarcoidosis (not 
as a pathognomonic test) 
• Most studies testing chitotriosidase showed a good correlation with disease outcomes 
and prediction of relapses  
• Measuring serum levels of ACE, chitotriosidase, sIL-2R and lysozyme may be useful for 
evaluating therapeutic responses 
• sIL-2R levels correlate with extrapulmonary/systemic sarcoidosis. 
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TABLE 1. Large studies (including more than 50 patients) testing serum ACE in patients with sarcoidosis. 











  (n) 
Loddenkemper  et al (1998) 12 Germany Unselected 715 443 61.96 NA 
Doubkova et al (2015) 13 Czech Unselected 306 124 40.52 68 U/L 
Ungprasert et al (2016) 20 US Unselected 251 104 41.43 ND 
Gupta (2002) 19 India Unselected 200 141 70.5 ND 
Maña et al (1999) 21 Spain Löfgren 186 71 50.35 ND 
Kahkouee et al (2016) 22 Iran Unselected 148 78 52.7 68 U/L 
Gillman et al (2007) 23 Australia Unselected 122 58 50.88 ND 
Vorselaars et al (2015) 24 The Netherlands Unselected 114 47 41.23 62 U/L 
Niederer et al (2018) 25 UK Ocular 110 85 77.27 52 U/L 
Sejdic et al (2018) 26 Denmark Unselected 101 48 47.52 52 U/L 
Febvay et al (2015) 27 France Ocular 83 50 60.24 62 U/L 
Nguyen et al (2017) 14 Japan Unselected 72 16 43.24 21 U/L 
Kawaguchi et al (2007) 15 Japan Ocular 67 35 58.33 ND 
Thelier et al (2008) 16 France Rheumatological 57 23 40.35 52 U/L 
Leonhard et al (2016) 17 The Netherlands Neurosarcoidosis 52 18 43.9 70 U/L 













TABLE 2. Sensitivity (SE), specificity (SP), positive predictive values (PPV) and negative predictive values (NPV) in studies testing 
serum ACE levels in patients with sarcoidosis. 
Author 
(year) Reference Country 
Sarcoidosis 
phenotype Controls 


















51 U/L 54 70 24 90 
          
          














82 U/L 22 99 90 87 
Kawaguchi 












Not detailed 58 95 90 77 













52 U/L 77 88 43 97 



































21 U/L 68 75 54 84 







52 IU/L 86 61 65 84 
          
100 IU/L 37 93 83 64 







32 U/L 66 54 nd nd 












TABLE 3. Other serum biomarkers tested in at least two different case-control studies: number of studies with significant results in comparison 
with control 
 








      (n) (n, %)   
Chitotriosidase M-M 5 509 5 (100%) Healthy controls, other pulmonary diseases 
Lysozyme M-M 2 148 1 (50%) Ocular diseases, healthy controls 
CXCL10 M-M 5 237 5 (100%) Healthy controls 
CXCL9 M-M 3 101 2 (67%) Healthy controls 
IL-10 M-M 3 141 1 (33%) Other cardiac diseases, healthy controls, other diseases 
IL-12 p40 M-M 2 105 2 (100%) Asthma, healthy controls 
IL-18 M-M 3 160 3 (100%) Healthy controls 
TNF-alpha M-M, T cells 2 133 2 (100%) Healthy controls 
sIL-2R T cells 4 179 3 (75%) Healthy controls 
BAFF B cells 3 158 3 (100%) Healthy controls 
Lymphopenia B cells 4 200 4 (100%) Uveitis, myelitis, healthy controls 
CRP Liver 6 491 5 (80%) Healthy controls, other pulmonary diseases 
SAA Liver 3 168 3 (100%) Healthy controls 
KL-6 Epithelium 3 139 3 (100%) Uveitis, healthy controls 
CC16 Epithelium 2 196 2 (100%) Healthy controls 
SP-D Epithelium 2 160 2 (100%) Healthy controls 
ICAM-1 Endothelium 2 46 1 (50%) Healthy controls 











M-M: monocyte-macrophage system 
 
Table 4. Summary of the results obtained for the main serum biomarkers in sarcoidosis: correlation with pulmonary and extrapulmonary involvement, 




involvement Therapeutic response Outcomes 
ACE levels Correlation Parenchymal involvement 
(14) 
BHL predictor (14) ↓ after Cs (36-39,41) Progressive/chronic disease 
(22,39,92) 
    Stages I/II vs 0 (38,51) Stage I vs II/III (33) ↓ after CQ (41) Active disease (32,33,44) 
      ↓ in Lofgren (35) ↓ after IFX (42,43)   
      Normal in EN (34)     
      Extrathoracic manifestations 
(34) 
    
      > 3 involved organs (14)     
      Severe or systemic cardiac 
involvement (89) 
    






ND Progressive/chronic disease 
(32,35,46-48,51,59) 
    Radiological stages (32,87) Number of organs involved 
(32) 
  Active/acute disease (49,50) 
    PFT (47)     Disease duration (32) 
            
CTO 
levels 
Correlation Stages I/II/III vs 0 (32) Extrapulmonary involvement 
(60) 
↓ after Cs (59,60) Active disease (32,60) 
    Stage III (59)   ↓ after adding ID (59) Chronic disease (59) 
    PFT (63)     Clinical/radiological/PFT 
worsening (63) 
          Predicting relapses (60) 











          Disease duration (32) 
  No 
correlation 
ND Extrapulmonary involvement 
(32) 
ND Chronic disease (32) 
      Number of organs involved 
(32) 
    
Lysozyme 
levels 
Correlation Parenchymal involvement 
(14,34,48) 
Extrathoracic involvement (34) ↓ after Cs (37,39) ND 
            
  No 
correlation 
ND > 3 involved organs (14) ND Progressive disease (48) 
      BHL (14)     
sIL-2R 
levels 
Correlation Stage II vs I (14) BHL (14) GC requirement (90) Progressive disease (35,48,86) 
    Stage I/II vs III (87) EN (87) ↓ after Cs (91) Need prolonged therapy (51) 
    Parenchymal involvement 
(14,48) 
> 3 involved organs (14) ↓ after IFX (42,43) Active/acute disease (51,90) 
      Extrapulmonary disease 
(42,87) 
    
      Spleen activity (88)     
      Systemic cardiac sarcoidosis 
(89) 
    
  No 
correlation 
PFT (47,87) ND GC response (87) Progressive/chronic disease 
(47,87,93) 
    Radiological stages (51)     Active disease (50) 
SAA levels Correlation ND ND ND Clinical outcome status (120) 
          Active disease (50,121) 
  No 
correlation 
PFT (120) Extrapulmonary disease (50) ND Progressive disease (48) 
    Parenchymal involvement 
(48) 













Correlation Parenchymal involvement 
(48) 
ND ND Progressive disease (48,77) 
    Stages II/III vs I (77)     Active disease (122) 
    Stages II/III vs 0/I (122)       
    PFT (77)       
    
Ground-glass opacity, 
nodules, interlobular 
septal thickening, traction 
bronchiectasis, 
architectural distortion 
and bronchial wall 
thickening (125) 
  
    
  
No 
correlation ND BHL (125) ND ND 
PFT: pulmonary functional tests; BHL: bilateral hilar lymphadenopathies; Cs: corticosteroids; IFX: infliximab; CQ: 












Table 5. Summary of the results obtained in the main studies including a head-to-head comparison between several serum biomarkers in 
sarcoidosis (YES = positive correlation, NO = lack of correlation, nd = not analysed) 
 
OUTCOME AUTHOR (year) Reference SERUM BIOMARKERS 
      ACE rs-IL2 CTO SAA Neopterin Lysozyme KL-6 
Activity Gungor et al (2015) 50 NO NO nd YES nd nd nd 
Popevic et al (2016) 32 YES nd YES nd nd nd nd 
Extrapulmonary disease Gungor et al (2015) 50 NO YES nd NO nd nd nd 
Popevic et al (2016) 32 NO nd NO nd nd nd nd 
Progression Prasse et al (2008) 51 NO YES nd nd YES nd nd 
Miyoshi et al (2010) 48 NO YES nd NO nd YES YES* 
Ziegenhagen et al 
(2003) 35 NO YES nd nd YES nd nd 
Bargagli et al (2013) 59 NO nd YES nd nd nd nd 
 
*Statistically-significant in multivariate analysis 
